type of report	**Current report**
number	6/2013
date of publication	2013-02-08 13:49:46
company	PHARMENA

January 2013 monthly report

1. Information on trends and events occurring in the Issuer's market environment
To the best knowledge of the Management Board, in January 2013 no trends or events occurred in the Issuer's market environment which could significantly influence financial results of the company.

On 8th January 2013, the Management Board of PHARMENA S.A. informed that, with reference to Company's Strategy 2012-2015 (released in current report no. 16/2012 of 13th April 2012), on 7th January 2013, a subsidiary company Cortria Corporation (USA) received notification that Health Canada (an authority supervising clinical trials in Canada) has completed the process of formal assessment of application for granting permission to carry out a bioavailability testing of an innovative anti-atherosclerotic medicinal product based on 1-MNA active substance (working name of the product – TRIA-662). Health Canada has not submitted any comments on the application, therefore, the first stage of the application's verification has concluded. The second stage of the application's verification will feature substantive evaluation of existing tests' results and work planned with respect to further bioavailability testing. Currently, the application has been filed for substantive evaluation. Having performed the substantive evaluation, Health Canada will decide on the submitted application.
Bioavailability testing is indispensible for carrying out phase II of clinical trials ("Proof of Concept") of anti-atherosclerotic medicinal product 1-MNA, in order to confirm its efficacy and absence of adverse side effects with increased doses. Bioavailability testing will be financed from funds obtained from the issue of series C shares.
Potential revenue after commercialisation of the anti-atherosclerotic medicinal product may prove to be very beneficial for the financial and economic situation of the Issuer in the future.

On 30th January 2013, with reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and the Company's announcement on the realisation of the Company's Strategy in the area of dietary supplement 1-MNA (published in current report no. 61/2012 of 17th September 2012), the Management Board of PHARMENA S.A informed of its choice of an EU member state to carry out the registration process of dietary supplement based on 1-MNA as new foodstuff within the European procedure.
The selected EU member state is United Kingdom. With reference to the above, the Company plans to submit its application for registration of novel food ingredient pursuant to Art. 4 of Regulation (EC) no. 258/97 to Food Standards Agency; Novel Foods, Additives and Supplements Division in London, UK.
The Company intends to register the dietary supplement in 2013. Positive registration will open EU markets for the product.
The 1-MNA dietary supplement is an innovative product that has a capacity to influence the risk biomarkers of cardiovascular diseases and to stimulate the endogenous (natural) production of prostacyclin. Low levels of prostacyclin in human organism increase the risk of atherosclerosis. Studies have shown that the concentration of endogenous 1-MNA in human organism decreases with age. 1-MNA dietary supplement can complement 1-MNA deficiency in the organism and therefore stimulate the production of prostacyclin which reduces the risk of atherosclerosis development.

Also, in January 2013, Pharmena S.A. continued its research and development work on new products and searched for new applications for active substances protected by patents and patent applications owned by the Company.

In January 2013, Pharmena S.A. expanded its product offer and carried out marketing actions in order to increase sales profit from its marketed products.

2. Achievement of the goals of an issue
In January 2013, Pharmena S.A. did not make any money expenditure directly on issue-related purposes. However, a subsidiary company Cortria Corporation spent in January 2013 its funds on production of tablets for clinical trials and legal service.

3. A list of all information published by the Issuer in the form of current reports in the reporting period from 1st January 2013 to 31st January 2013

During the period covered by this report, Pharmena S.A. published the following reports in EBI system:
• Current report no. 1/2013 of 8th January 2013 - Completion of formal assessment of application to Health Canada for granting permission for bioavailability testing of 1-MNA medicinal product
• Current report no. 2/2013 of 11th January 2013 - Dates of publishing of periodical reports in 2013
• Current report no. 3/2013 of 14th January 2013 - December 2012 monthly report
• Current report no. 4/2013 of 30th January 2013 - Selection of a country of registration of 1-MNA dietary supplement

During the period covered by this report, Pharmena S.A. published the following reports in ESPI system:
• Current report no. 1/2013 of 17th January 2013 - Information on transactions in financial instruments of the Issuer
• Current report no. 2/2013 of 25th January 2013 - Information on transactions in financial instruments of the Issuer
• Current report no. 3/2013 of 25th January 2013 - Information on transactions in financial instruments of the Issuer

4. Investor's calendar for February 2013

14th February 2013 – publication of Q4 2012 quarterly report
Publication of January 2013 monthly report until 14th February 2013

Legal basis: Resolution No. 795/2008 of the Warsaw Stock Exchange Management Board dated 31st November 2008 concerning the adoption of the codes of best practice applicable on the NewConnect market, Appendix 1, point 16.

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board